Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis

2006 ◽  
Vol 27 (5) ◽  
pp. 467-472 ◽  
Author(s):  
Yasunori Kageyama ◽  
Eiji Torikai ◽  
Akira Nagano
Sign in / Sign up

Export Citation Format

Share Document